Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome

NCT ID: NCT03457324

Last Updated: 2020-08-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 392 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-08
• Study Completion Date: 2021-06-30

Brief Summary

This is a multicenter, randomized, double-blind, placebo controlled clinical trial, in order to evaluate the efficacy and safety of Chinese Medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome. All patients will be evaluated for study eligibility at Visits 1 (baseline) and 2 (2 weeks). On visit 2, patients who meet the criteria will be randomly assigned to receive 8-week treatment of either JCM-16021 Granules or JCM-16021 placebo Granules. The investigators, research assistants and participants are not aware of the treatment assignments throughout the study. Treatment codes will only be broken after the completion of study. The assessments at Visit 3 (4-week post treatment) and at visit 4 (end of 8-week treatment) are used to measure treatment response (i.e. changes from baseline). Assessment at visit 5 (end of 8-week follow up) is to determine any sustained response to treatment. All the visits will be carried out in HKBU and CUHK clinics.

Detailed Description

Sample size calculation:

Sample size is calculated on the basis of primary efficacy variables. From our previous study, the global assessment of improvement (GAI) were 52% in herbal medicine group and 32% in western medicine group, respectively. According to the references (Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Alimentary pharmacology & therapeutics 2003; 18 (6): 569-580), the investigational drug is more effective than placebo (the overall improvement rate of symptoms is 15%), using StudySize2.0 software to calculate the sample size, assuming the improvement in the treatment group is 52%. In order to detect a difference with a two-side p value <0.05 and 80% statistical power, we will need to recruit 166 patients per arm. Further assuming a 15% dropout rate, we conclude that a total of 392 patients (196 per arm) will be recruited to ensure statistically significant results.For the number of cases distribution between centers, according to the references (Lai D,Chang KC, Rahbar MH, Moye LA. Optimal Allocation of Sample Sizes to Multicenter Clinical Trials. Journal of biopharmaceutical statistics 2013; 23 (4): 818-828) , from the following equation, we will consider the center about the patient flow, traffic, treatment,costs and other possible factors, we will use the formula below to estimate the number of cases that will be recruited in each center.

Research medical record and Electronic Database:

All patients should be observed and assessed based on clinical trial protocol and the investigators need to document in the medical record accurately and clearly. Research medical record is the source document which cannot be altered. Any correction should not change the original record and can only be added in a way of narration with reasons. The doctor participated in the clinical trial needs to sign and date the record. An electronic database will be created. Each study site will input their own data and be responsible for its accuracy. A chief statistician will be responsible for data cleaning and data analysis.

Analysis parameters:

All parameters and study elements will be analyzed. The statistical analysis will be performed using SAS 9.1 and SPSS software.

Analysis sets:

Full analysis set (FAS): The analysis will be conducted according to the intention-to-treat (ITT) principle which means to eliminate the participants with a minimum and reasonable method. ITT population refers to all participants who go through randomization, enter double-blind treatment period, and receive IMP at least one time. Missing values of efficacy will be imputed by the last-observation-carried forward (LOCF) method. Per-protocol set (PP): PP population refers to all participants who complete relative observation according to protocol requirement and are confirmed to meet following conditions: ① compliance between 80% and 120%; ② not taking probihited medications during the process of trial; ③ meeting inclusion criteria and not fitting any exclusion items; ④ completing all planned visits and necessary items of CRF. Missing values of this set will still be processed as missing data and not be imputed. Safety analysis set: Population for safety analysis refers to all participants who enter the trial, receive medication at least one time and have suitable follow-up data for safety analysis. All safety data including AEs and laboratory results from participants will be assessed.16.3 Statistical analysis technique Baseline data (gender, age, race, weight, height, vital signs, course of IBS, history of smoking and alcohol) will be descriptively summarized. Differences of measurement data between the groups will be assessed with the use of t-test for normally distributed continuous variables and Wilcoxon signed rank test for non-normally distributed. Differences of enumeration data between the groups will be assessed with the use of chi-square test or CMH test when considering multicenter character. Measurement data of different groups in each visit will be reported as mean ± standard deviation (SD). Intra-group comparisons between baseline and each visit will be conducted by using paired t-test (or Wilcoxon signed rank test). Comparisons between groups will be conducted by using an analysis of variance (ANOVA), with other confounding factors like multicenter character conducting the covariate analysis. Statistical analysis for the data which do not meet above conditions (e.g. non-normal) will be conducted with the use of non-parametric test. Enumeration data of different groups in each visit will be reported as frequency (proportion). Comparisons between groups will be assessed with the use of X2 test (CMH test) or non-parametric test. Dropout analysis: Dropout analysis will be conducted with the use of chi-square test. If the data do not conform to chi-square test (data include 0, or theoretical frequency is below 1), Fisher's exact test will be used. Compliance analysis: Compliance analysis will be conducted with the use of chi-square test. If the data do not conform to chi-square test (data include 0, or theoretical frequency is below 1), Fisher's exact test will be used.

Hypothesis testing:

This trial will conduct superiority analysis firstly. Other difference test will be conduct by two-sided test. The statistical significance will be defined as two-sided P-value of ≤0.05 without any special explanation.

Efficacy analysis:

The efficacy analysis will be conducted with the use of PP analysis and ITT analysis in the meantime. Comparisons of measurement data will be conducted by using analysis of covariance (ANCOVA), with treatment group and trial center as a factor in the model and baseline as the covariate. Comparisons of measurement data will be conducted by using chi-square test or CMH chi-square test when considering multicenter character. Meanwhile, superiority analysis between experimental group and control group will be conducted based on primary efficacy variables. Superiority test depends on interval method.

Safety analysis:

Extent of exposure: Descriptive statistics will be conducted according to the exposure dose and time of medication in different groups. AEs analysis: Comparisons of incidence rate of AEs between groups will be conducted with the use of X2 test. And investigators need to list and describe the AEs happened in this trial. If the data do not conform to X2 test (data include 0, or theoretical frequency is below 5), Fisher's exact test will be used.

Data management:

CRFs are filled in by investigators and study coordinators, other assessment forms by every participant (including dropout cases). Data processing will be conducted in accordance with the following protocol:

1. Verification of CRFs: Study coordinators need to verify CRFs before inputting.

2. Data verification needs to be conducted successively in the following two steps:

1. Verify the consistency and logicality of data: Review contents of data range and logicality are determined by the range of each indexes and the interrelation. Corresponding software will also be written to correct the incorrect data.

2. Compare database and CRFs by manual testing. Selectively counter check 10% CRFs with participants' medical notes to know the quality of inputting and analyze and handle the existing problems.

3. Data inspection and closure of database: After verifying the validity of established database and statistical protocol, principal investigators, will lock the data. The locked data are not allowed to change. Confirmed problems found after locking will be handled in the process of statistical analysis. All mistakes and modification should be recorded and kept properly.

Conditions

Irritable Bowel Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

JCM-16021 Group

JCM-16021 granules 8g/sachet, three times daily for 8 weeks.

Group Type: EXPERIMENTAL

JCM-16021

Intervention Type: DRUG

This prescription with seven ingredients.

Placebo Group

Placebo granules 8g/sachet, three times daily for 8 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

JCM-16021

This prescription with seven ingredients.

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. fulfill the diagnostic criteria of diarrhea-predominant IBS (IBS-D);

2. fulfill the diagnostic criteria of diarrhea with TCM pattern of liver depression and spleen deficiency (LDSD);

3. age of 18-65 years (inclusive);

4. participants are voluntary and provide written informed consent.

Exclusion Criteria

1. constipation-predominant, mixed or unsubtyped IBS patients;

2. severe diseases on heart, liver and kidney, hematology or cancer which is diagnosed by traditional Chinese medicines;

3. medical history of organic gastrointestinal diseases (e.g. inflammatory bowel diseases, intestinal tuberculosis, colon polyps), or systemic diseases which could affect gastrointestinal motility (e.g. hyperthyroidism, diabetes mellitus, chronic renal failure, neuropsychiatric diseases) which is diagnosed by traditional Chinese medicines;

4. current concomitant medication with effects on gastrointestinal function (e.g. anticholinergic drugs, calcium channel blockers, 5-HT3 receptor antagonists, antidiarrheal agents, antacids, prokinetic agents, antidepressants, anxiolytics and intestinal flora regulating drugs);

5. medical history of abdominal surgery (e.g. cholecystectomy, etc.);

6. drug or food allergies;

7. pregnancy or breast-feeding;

8. medical history of neurological diseases or psychiatric disorders;

9. currently participating in another clinical trial;

10. taking IBS treatment drugs within 1 week.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chinese University of Hong Kong

OTHER

Sponsor Role: collaborator

ZhaoXiang Bian

OTHER

Sponsor Role: lead

Responsible Party

ZhaoXiang Bian

Chair Professor of Clinical Division

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Justin Wu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

Chinese Medicine Clinics of Hong Kong Baptist University

Hong Kong, Hong Kong, China

Site Status: RECRUITING

Institute of Digestive Disease, The Chinese University of Hong Kong

Hong Kong, , China

Site Status: NOT_YET_RECRUITING

Countries

China

Central Contacts

Zhaoxiang Bian, ph.D

Role: CONTACT

bzxiang@hkbu.edu.hk

34112905 ext. 34112929

Facility Contacts

Zhao-xiang Bian, PhD

Role: primary

bzxiang@hkbu.edu.hk

852-34112905

Justin Wu, M.D

Role: primary

justinwu@cuhk.edu.hk

2632 3524

References

Zhai L, Zheng Y, Lo CW, Xu S, Jiang X, Liu Q, Ching JY, Ning Z, Bao G, Yang W, Zhang Q, Cheng CW, Lam WC, Chan KL, Zhang X, Lam PY, Wu XY, Zhong LLD, Cao PH, Koh M, Cheong PK, Lin Z, Lin C, Zhao L, Wong XHL, Wu JC, Bian Z. Butyrate-producing commensal bacteria mediates the efficacy of herbal medicine JCM-16021 on abdominal pain in diarrhea-predominant irritable bowel syndrome: a randomized clinical trial. Phytomedicine. 2025 Sep;145:157040. doi: 10.1016/j.phymed.2025.157040. Epub 2025 Jul 1.

Reference Type: DERIVED

PMID: 40639240 (View on PubMed)

Zheng Y, Ching J, Cheng CW, Lam WC, Chan KL, Zhang X, Lam PY, Wu XY, Zhong LLD, Cao PH, Lo CW, Cheong PK, Lin Z, Koh M, Wu J, Bian ZX. Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial. Chin Med. 2021 Nov 13;16(1):117. doi: 10.1186/s13020-021-00530-2.

Reference Type: DERIVED

PMID: 34774080 (View on PubMed)

Other Identifiers

ITS-148-14FP

Identifier Type: -

Identifier Source: org_study_id